The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

Viewpoint: Targeting amyloid deposits isn’t working. It’s time for a new approach for Alzheimer’s treatments

| | May 10, 2019

If insanity is doing the same thing over and over again but expecting different results, then the last decade or so of Alzheimer’s disease drug development has been insane. Three carefully designed, well-executed, and fully resourced trials targeting amyloid protein in the brain as the cause of Alzheimer’s disease have failed. It’s long past time to take a new approach to this mind-robbing disease.

What’s next? A number of small companies are working on other-than-amyloid approaches to Alzheimer’s disease and dementia. Although these companies have had little success in getting the attention of investors and pharmaceutical partners, the failure of aducanumab is giving these non-amyloid strategies the attention they deserve.

Related article:  Treating genetic disorders before birth? CRISPR cures mouse disease in the womb

What we today call Alzheimer’s disease likely stems from several different causes, so exploring multiple strategies is important. And because Alzheimer’s is such a complex disease, there is a very low probability that a single therapy will treat all patients with dementia or be effective throughout their lifetimes. This complicates things, but that’s biology and it increases the need for multiple options.

Now that the insanity of amyloid is behind us, it’s time to make real progress.

Read full, original post: After amyloid failures, it’s time to take a new tack for treating Alzheimer’s

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend